PT  - JOURNAL ARTICLE
AU  - Shapiro, Adrienne E.
AU  - Bender Ignacio, Rachel A.
AU  - Whitney, Bridget M.
AU  - Delaney, Joseph A.
AU  - Nance, Robin M.
AU  - Bamford, Laura
AU  - Wooten, Darcy
AU  - Keruly, Jeanne C.
AU  - Burkholder, Greer
AU  - Napravnik, Sonia
AU  - Mayer, Kenneth H.
AU  - Webel, Allison R.
AU  - Kim, H. Nina
AU  - Van Rompaey, Stephen E.
AU  - Christopoulos, Katerina
AU  - Jacobson, Jeffrey
AU  - Karris, Maile
AU  - Smith, Davey
AU  - Johnson, Mallory O.
AU  - Willig, Amanda
AU  - Eron, Joseph J.
AU  - Hunt, Peter
AU  - Moore, Richard D.
AU  - Saag, Michael S.
AU  - Mathews, W. Christopher
AU  - Crane, Heidi M.
AU  - Cachay, Edward R.
AU  - Kitahata, Mari M.
AU  - ,
TI  - Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020
AID  - 10.1101/2021.10.15.21265063
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.15.21265063
4099  - http://medrxiv.org/content/early/2021/10/18/2021.10.15.21265063.short
4100  - http://medrxiv.org/content/early/2021/10/18/2021.10.15.21265063.full
AB  - Background Understanding the spectrum of SARS-CoV-2 infection and COVID-19 disease in people with HIV (PWH) is critical to provide clinical guidance and implement risk-reduction strategies.Objective To characterize COVID-19 in PWH in the United States and identify predictors of disease severity.Design Observational cohort study.Setting Geographically diverse clinical sites in the CFAR Network of Integrated Clinical Systems (CNICS)Participants Adults receiving HIV care through December 31, 2020.Measurements COVID-19 cases and severity (hospitalization, intensive care, death).Results Of 16,056 PWH in care, 649 were diagnosed with COVID-19 between March-December 2020. Case fatality was 2%; 106 (16.3%) were hospitalized and 12 died. PWH with current CD4 count <350 cells/mm3 (aRR 2.68; 95%CI 1.93-3.71; P<.001) or lowest recorded CD4 count <200 (aRR 1.67; 95%CI 1.18-2.36; P<.005) had greater risk of hospitalization. HIV viral load suppression and antiretroviral therapy (ART) status were not associated with hospitalization, although the majority of PWH were suppressed (86%). Black PWH were 51% more likely to be hospitalized with COVID-19 compared to other racial/ethnic groups (aRR 1.51; 95%CI 1.04-2.19, P=.03). Chronic kidney disease (CKD), chronic obstructive pulmonary disease, diabetes, hypertension, obesity, and increased cardiovascular and hepatic fibrosis risk scores were associated with higher risk of hospitalization. PWH who were older, not on ART, with current CD4 <350, diabetes, and CKD were overrepresented amongst PWH who required intubation or died.Limitations Unable to compare directly to persons without HIV; underestimate of total COVID-19 cases.Conclusions PWH with CD4 <350 cells/mm3, low CD4/CD8 ratio, and history of CD4 <200, have a clear excess risk of severe COVID-19, after accounting for comorbidities also associated with severe outcomes. PWH with these risk factors should be prioritized for COVID-19 vaccination, early treatment, and monitored closely for worsening illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this study and for CNICS came from the National Institute of Allergy and Infectious Diseases (NIAID) [CNICS R24 AI067039; UW CFAR NIAID Grant P30 AI027757; UAB CFAR grant P30 AI027767; UNC CFAR grant P30 AI50410; UCSD CFAR grant P30 AI036214; Case Western Reserve University CFAR grant P30 AI036219; Fenway Health/Harvard CFAR grant P30 AI060354, UCSF CFAR grant P30 AI027763 and JHU CFAR grant P30 AI094189] and the National Institute on Drug Abuse (NIDA) [R01DA047045].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs from all participating institutions gave ethical approval for this work: Case Western Reserve University; Fenway Health/Harvard; Johns Hopkins University; University of Alabama, Birmingham; University of North Carolina, Chapel Hill; University of California, San Diego; University of California, San Francisco; University of WashingtonI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are available from the CNICS Study and are available upon application to the CNICS Investigators. https://sites.uab.edu/cnics/submit-a-proposal/